Bio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report released on Tuesday morning. The brokerage issued a sell rating on the stock.

Separately, Roth Mkm upped their target price on Bio-Path from $12.00 to $40.00 and gave the stock a buy rating in a research report on Wednesday, March 27th.

Bio-Path Trading Up 29.6 %

Shares of Bio-Path stock opened at $4.20 on Tuesday. The stock has a 50-day moving average price of $5.50 and a 200 day moving average price of $8.53. The company has a market cap of $2.86 million, a P/E ratio of -0.10 and a beta of 0.35. Bio-Path has a 1 year low of $2.70 and a 1 year high of $44.80.

Bio-Path (NASDAQ:BPTH) last announced its quarterly earnings data on Friday, March 8th. The company reported ($5.40) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($5.40). During the same period in the previous year, the company earned ($10.60) earnings per share. On average, equities analysts forecast that Bio-Path will post -18.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC acquired a new position in shares of Bio-Path during the 1st quarter valued at about $38,000. Citadel Advisors LLC acquired a new position in shares of Bio-Path during the 3rd quarter valued at about $35,000. Renaissance Technologies LLC acquired a new position in shares of Bio-Path during the 2nd quarter valued at about $70,000. Vanguard Group Inc. increased its holdings in shares of Bio-Path by 77.5% during the 4th quarter. Vanguard Group Inc. now owns 270,029 shares of the company’s stock valued at $125,000 after acquiring an additional 117,914 shares during the last quarter. Finally, Walleye Capital LLC acquired a new position in shares of Bio-Path during the 3rd quarter valued at about $77,000. Institutional investors and hedge funds own 5.74% of the company’s stock.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.